Back to search results

UPBEAT Study: Beta Blockers and Genetics for Heart Failure

This study, called UPBEAT, is looking at how well beta blocker medication works in people with a type of heart failure where their heart's pumping ability (ejection fraction) is mildly reduced (between 41% and 50%). Researchers will use a tool called polygenic scores, which look at differences in your genes, to understand how these genetic differences might affect your response to beta blockers. The study will also measure changes in the size of your heart's main pumping chamber (left ventricle end-systolic volume index) using an MRI to see the effects of beta blockers. You could be eligible if you are 18-89 years old and have a recent diagnosis of heart failure with an ejection fraction between 41% and 50%. The current status of this study is unclear.

Study design
This is an interventional study that plans to enroll 10 participants. Participants will be randomly assigned to receive beta blocker medication according to the study's plan.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, change in left ventricle end systolic volume index, is measured within 6 months of randomization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07054489

UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

Recruiting
NAAges 18–89InterventionalTreatment
David Lanfear
~10 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:Beta blocker

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in left ventricle end systolic volume index
Measured over Within 6 months of randomization

Conditions

Heart Failure
Polygenic Score

Explore related trials

Heart Failure

NCT07054489

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Henry Ford Health

    Detroit, Michiganstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Lanfear, MD · PRINCIPAL_INVESTIGATOR · Henry Ford Health

Who to contact

Whitney Cabral, MS
[email protected]
313-949-6616
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-89 years
Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent)
Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time
Expected ability to fully participate in study (can tolerate study processes, no long travel)

Exclusion

Unable to provide informed consent
Previous documented EF =\< 35%
Currently on BB =\>25% target dose
Uncontrolled hypertension (systolic BP \> 180 at enrollment)
Has contraindications to all BB or intolerance to metoprolol
Systolic BP \< 100 or heart rate \<70
Current cancer requiring active treatment
Heart transplant or LVAD or expected in the next year
Life expectancy \< 1 year for any reason
Dialysis dependence or ESRD
MI/ PCI or other cardiac surgery within 90 days prior to enrollment or planned in the future
Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina)
If PI decides for any reason participation in trial is not in best interest of the patient
Has a contraindication to completing MRI procedures

What this trial measures

  • Change in left ventricle end systolic volume indexWithin 6 months of randomization

    LVESVi, measured in mL per square meter; assessed by cardiac MRI